The present invention relates to a kit for quantitatively examining mRNA of hair loss–related genes from hair, preferably from hair follicles, and a method for diagnosing or predicting causes of hair loss using same, and a method for alleviating, preventing, or treating hair loss. According to the present invention, testing from RNA extraction of hair loss–related genes to quantitative PCR can be performed using a small amount of hair, thereby enabling simple and rapid identification of the cause of hair loss and allowing for personalized hair health management. In addition, since no separate laboratory is required for on-site testing and anyone can easily perform testing and result acquisition through simple training, a user can easily perform the testing even in small clinics or facilities without clinical laboratories.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
2.
COMPOSITE MATERIAL FOR THERMAL BLOCK OF THERMAL CYCLER, AND THERMAL BLOCK OF LOW-SPECIFIC-HEAT THERMAL CYCLER, MANUFACTURED USING SAME
The present invention relates to a composite material for a thermal block of a thermal cycler. The composite material has both low specific heat characteristics and remarkably improved thermal conductivity, and thus, when the temperature of a thermal block, which is manufactured using the composite material, rises and falls, deviation in temperature change rate between a plurality of unit thermal blocks and/or in different areas in a unit thermal block can be remarkably reduced such that a PCR thermal cycler including the thermal block can ensure reliability even in ultrafast PCR.
A PCR plate includes: a body having at least one reaction well; an insertion portion extending from the body to be inserted into a nucleic acid extraction cartridge and having an injection port, into which a nucleic acid solution is injected; a flow channel, along which the nucleic acid solution flows from the injection port to the reaction well; and a blocking member mounted on the body and blocking a reverse flow of the nucleic acid solution from the reaction well towards the flow channel.
The purpose of the present disclosure is to provide a multi-well plate for culturing a single microorganism, capable of conveniently and rapidly dividing and culturing a culture medium containing a single microorganism in a plurality of multi-wells. The multi-well plate of the present disclosure is economical because a special device is not additionally used, and a method for culturing a single microorganism using same can efficiently culture a single microorganism in multi-wells without a process of diluting a culture medium in each well.
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 1/32 - Inoculateur ou échantillonneur du type à champs multiples ou en continu
6.
AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide which can highly specifically and efficiently inhibit an amphiregulin expression and, preferably, a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or DNA/RNA hybrid, a double-stranded oligonucleotide structure comprising the double-stranded oligonucleotide, nanoparticles comprising the double-stranded oligonucleotide structure, and a fibrosis or respiratory disease preventive or therapeutic use thereof.
An electromagnetic shielding composition according to the present invention is directed to an electromagnetic shielding composition capable of forming an electromagnetic shielding film with excellent electromagnetic shielding capacity and flexibility and, specifically, comprises: a core-shell structured metal nanowire comprising a core containing copper and a shell containing silver on the core; and plate-like metal particles selected from plate-like silver particles and silver-coated plate-like copper particles.
H05K 9/00 - Blindage d'appareils ou de composants contre les champs électriques ou magnétiques
8.
Composition for Administration of Double-Stranded Oligonucleotide Structures Using Ultrasonic Nebulizer for Prevention or Treatment of Respiratory Viral Infection Including COVID-19, Pulmonary Fibrosis Caused by Viral Infection, or Respiratory Diseases
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Han-Oh
Lee, Sang-Kyu
Yun, Sung-Ll
Kwon, Oh Seung
Goh, Eun-Ah
Goh, Young-Ho
Park, Jun-Hong
Song, Kang
Kim, Jangseon
Lee, Mi-Sun
Choi, Soon-Ja
Abrégé
The present invention relates to a composition for administering a double-stranded oligonucleotide structure using an ultrasonic nebulizer. According to the method, the double-stranded oligonucleotide according to the present invention forms self-assembled nanoparticles, which are 90 nm in size and have a neutral charge, and it is possible to deliver the double-stranded oligonucleotide specifically to the nasal cavity and lungs while maintaining not only the same concentration, molecular weight, purity, nanoparticle size, and osmolality as those of the stock material but also the target gene inhibitory activity without cytotoxicity. Thus, the present invention may be useful for the prevention or treatment of respiratory viral infections including COVID-19, pulmonary fibrosis caused by viral infection, or respiratory diseases.
The present invention relates to the structure of an analysis plate applied to a high-speed polymerase chain reaction (PCR), and to a PCR analysis plate used for implementing an analysis of a real-time PCR, a real-time nested PCR and a post-PCR lateral flow hybridization reaction. The present invention is provided with: a check valve for enabling the maintaining of positive pressure when an elastic film expands into a convex form by having a solution pushed therein by the positive pressure; a lateral flow analysis module for analyzing a post-PCR follow-up PCR or lateral flow; and a shut-off valve enabling the controlling of the movement of the solution after each reaction ends.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
09 - Appareils et instruments scientifiques et électriques
Produits et services
Chemical reagents for research use; reagents for protein quantitative analysis for research use; micro arrayed DNA chemical reagents for research use; reagents for extraction of protein used for research; research test kits comprising reaction buffer, magnetic particles, elution buffer, washing buffer, template, for separation and purification of protein used for research; reagents for protein expression used for research; research test kits, comprising primarily reaction buffer, magnetic particles, elution buffer, washing buffer, expression vectors, and also featuring template in the nature of plasmids, polymerase chain reaction (PCR) products or mRNA, for expression of protein or polypeptides used for research; reagents for synthesis of protein used for research; research test kits, comprising primarily reaction buffer, magnetic bead, elution buffer, washing buffer, and also featuring template in the nature of plasmids, polymerase chain reaction (PCR) products or mRNA, for synthesis of protein or polypeptides used for research; research test kits comprising reagents for polymerase chain reaction for scientific and research use; research test kits comprising reagents for amplifying nucleic acids for scientific and research use Nucleic acid analyzers for scientific research use; protein and peptide synthesizers for scientific research use; protein analyzers for scientific research use; protein extractors for scientific research use; laboratory apparatus and computer systems for use in protein purification; laboratory apparatus and computer systems for use in nucleic acid purification; laboratory apparatus for amplifying nucleic acids; laboratory apparatus for in-vitro transcription and translation of nucleic acid; laboratory apparatus for isolating protein; laboratory apparatus for extracting nucleic acid
11.
PCR PLATE, NUCLEIC ACID EXTRACTION CARTRIDGE, AND POLYMERASE CHAIN REACTION DEVICE COMPRISING SAME
A PCR plate according to the present invention comprises: a body part having at least one reaction well; an insertion part extending from the body part, inserted into a nucleic acid extraction cartridge, and having an injection inlet into which a nucleic acid solution is injected; a flow path section that allows flow of the nucleic acid solution from the injection inlet to the reaction well; and a blocking part that is mounted on the body part and blocks backflow of the nucleic acid solution from the reaction well toward the flow path section.
The present invention relates to a metal nanowire having a core-shell structure, the metal nanowire being conductive and transparent while having excellent oxidation stability, and being capable of maintaining excellent oxidation stability even after a secondary process using the metal nanowire of the present invention. Specifically, the metal nanowire having a core-shell structure, according to the present invention, comprises a core containing copper, and a shell containing silver on the core, wherein the ratio (D/L) of the diameter (D) of the core to the thickness (L) of the shell is 10-60, the thickness of the shell is 5-40 nm, and the peak intensity (I1) of Ag 3d5/2 of silver and the peak intensity (I2) of Cu 2p3/2 of copper in the X-ray photoelectron spectrum satisfy the following Equation 1.
The present invention relates to a metal nanowire having a core-shell structure, the metal nanowire being conductive and transparent while having excellent oxidation stability, and being capable of maintaining excellent oxidation stability even after a secondary process using the metal nanowire of the present invention. Specifically, the metal nanowire having a core-shell structure, according to the present invention, comprises a core containing copper, and a shell containing silver on the core, wherein the ratio (D/L) of the diameter (D) of the core to the thickness (L) of the shell is 10-60, the thickness of the shell is 5-40 nm, and the peak intensity (I1) of Ag 3d5/2 of silver and the peak intensity (I2) of Cu 2p3/2 of copper in the X-ray photoelectron spectrum satisfy the following Equation 1.
I
2
/
I
1
≤
0
.
2
(
Equation
1
)
C09D 7/62 - Adjuvants non macromoléculaires inorganiques modifiés par traitement avec d’autres composés
13.
COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT
The present invention relates to a composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded miRNA as an active ingredient and, more specifically, to: miR-3139, miR-3189, miR-3199 or miR-8485, which are double-stranded miRNA; a double-stranded oligonucleotide structure comprising same; or a pharmaceutical or cosmetic composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising nanoparticles containing the structure as an active ingredient. A composition according to the present invention can prevent hair graying and reduce the rate of progress thereof by activating melanocytes and promoting melanogenesis and can allow the hair already affected by graying to be improved to a state before graying. In addition, the composition promotes the activation of melanocytes and the proliferation of dermal papilla cells and keratinocytes that are present in hair follicles, and induces outer root sheath development and hair growth so that the effects of promoting hair growth and/or preventing hair loss can be exhibited.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61Q 5/00 - Préparations pour les soins des cheveux
A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
14.
COMPOSITION FOR DETECTING SPRING VIRAEMIA OF CARP, AND DETECTION METHOD THEREFOR
The present invention relates to a composition for detecting Spring viraemia of carp, and a detection method therefor, and, specifically, to: a primer pair for amplifying genes encoding a matrix protein or a nucleocapsid of Spring viraemia of carp; a composition and a kit for detecting Spring viraemia of carp, each comprising same; and a method for detecting Spring viraemia of carp by using same.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
15.
COMPOSITE MATERIAL FOR THERMAL BLOCK OF THERMAL CYCLER, AND THERMAL BLOCK OF LOW-SPECIFIC-HEAT THERMAL CYCLER, MANUFACTURED USING SAME
The present invention relates to a composite material for a thermal block of a thermal cycler. The composite material has both low specific heat characteristics and remarkably improved thermal conductivity, and thus, when the temperature of a thermal block, which is manufactured using the composite material, rises and falls, deviation in temperature change rate between a plurality of unit thermal blocks and/or in different areas in a unit thermal block can be remarkably reduced such that a PCR thermal cycler including the thermal block can ensure reliability even in ultrafast PCR.
The present invention relates to a double-helix oligonucleotide construct comprising a double-stranded miRNA and a composition for preventing or treating cancer comprising the same. More particularly, the present invention relates to a double-helix oligonucleotide construct comprising miR-544a characterized by a method that effectively inhibits the proliferation of cancer cells or induces a voluntary death of cancer cells, and an anticancer composition comprising the construct.
The invention relates to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system and, more specifically, to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system, in which dispensing of a liquid sample and extraction, amplification and testing of nucleic acids are integrally carried out. The sample tube opening/closing device includes: a housing that forms an inner space isolated from the outside and includes a door for carrying in/out a multi-well plate for biological samples, including a plurality of sample tubes in which biological samples are accommodated; and a sample tube opening/closing part that is installed in the inner space to be spaced apart from the multi-well plate for biological samples and automatically opens and closes the sample tubes.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
The present invention relates to a method for isolating a nucleic acid by using: a binding buffer containing acetic acid or phosphoric acid; and the pH difference between binding and washing buffers, and an elution buffer, wherein silica magnetic particles are added to a biological sample including a nucleic acid to which a binding buffer containing acetic acid, phosphoric acid, etc., has been added, thereby binding the nucleic acid to the magnetic particles, after which a magnetic field is applied to separate the magnetic particles, and the nucleic acid is purified in a basic pH elution buffer. The method uses the pH difference, and can isolate the nucleic acid more quickly and efficiently than centrifugation or gravity separation. In addition, since ethanol is not used, high-purity nucleic acid can be isolated and purified to obtain more accurate results in subsequent experiments.
The present invention relates to a nucleic acid amplification test apparatus, and an automatic sample analysis system having same and, more particularly, to a nucleic acid amplification test apparatus in which separation and purification, dispensation, amplification, and testing of samples are performed integrally, and an automatic sample analysis system having same. Disclosed in the present invention is a nucleic acid amplification test apparatus comprising: a housing (30) having an inner space (S1) isolated from the outside; a multi-well plate insertion unit (100) into which a multi-well plate (40) having a plurality of reaction tubes (1) accommodating a target nucleic acid solution is inserted through an automatic purification and dispensing apparatus (10); a sealing plate insertion unit (200) into which a sealing plate (50) having a sealing means for sealing the inlets of the plurality of reaction tubes (1); a fluorescence detection unit (400) disposed on an upper side of the sealing plate insertion unit (200) and detecting a target nucleic acid in the reaction tubes (1); and a temperature control block (500) disposed on a lower side of the multi-well plate insertion unit (100) and controlling the temperature of the reaction tubes (1), wherein the reaction tubes (1) are moved relatively so as to be adjacent to the sealing means to be then sealed by the sealing means.
The present invention relates to a double-stranded oligonucleotide capable of inhibiting amphiregulin expression in a very specific and highly efficient manner, preferably a double-stranded oligonucleotide comprising a sequence in the form of an RNA/RNA, DNA/DNA or DNA/RNA hybrid, and the use of a double-stranded oligonucleotide structure, which comprises the double-stranded oligonucleotide, and nanoparticles, for preventing or treating obesity.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
The present invention relates to a double-stranded oligonucleotide which can highly specifically and efficiently inhibit an amphiregulin expression and, preferably, a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or DNA/RNA hybrid, a double-stranded oligonucleotide structure comprising the double-stranded oligonucleotide, nanoparticles comprising the double-stranded oligonucleotide structure, and a fibrosis or respiratory disease preventive or therapeutic use thereof.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Functional cosmetics; cosmetics for scalp; cosmetic preparations for the hair and scalp; non-medicated scalp stimulating preparations, not for medical use; non-medicated toners for scalp, not for medical use
23.
DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR TREATING COVID-19 CONTAINING SAME
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Han-Oh
Kim, Jangseon
Lee, Mi Sun
Choi, Soonja
Lee, Eun-Kwang
Byun, Sang Jin
Abrégé
The present invention relates to: a double-stranded oligonucleotide which can highly specifically and efficiently inhibit the proliferation of Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), preferably a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or a DNA/RNA hybrid; a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide; and a use thereof for treating COVID-19.
Aphanomyces invadansAphanomyces invadans and/or internal transcribed spacer 1 (ITS1) thereof, a composition for detecting epizootic ulcerative syndrome comprising same, a detection kit therefor, and a method for detecting epizootic ulcerative syndrome using same.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires
25.
COMPOSITION FOR DETECTING WHITE SPOT SYNDROME VIRUS AND METHOD FOR DETECTING SAME
The present invention relates to a composition for detecting a white spot syndrome virus and a method for detecting same and, particularly, to a pair of primers for amplifying VP664 and/or VP28, which are genes expressing envelope proteins of a white spot syndrome virus, a composition for detecting a white spot syndrome virus comprising same, a kit for detection, and a method for detecting a white spot syndrome virus using same.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Functional cosmetics; cosmetics for scalp; hair strengthening treatment lotions; hair stabilizers; hair care agents; hair lotions; hair care preparations; hair conditioner; hair care lotions; hair care creams; cosmetic preparations for hair care; hair essences; hair essence mists; beauty creams; cosmetic preparations for skin care; face and body lotions; make-up preparations for the face and body; face and body beauty creams; lotions for face and body care; cosmetic creams and lotions; face and body creams; shampoo; beauty masks; hair colorants; colouring preparations for cosmetic purposes; skin whitening preparations; hair cleaning preparations; cosmetic preparations for the hair and scalp; depilatory creams; depilatory preparations; depilatories; scalp stimulating preparations (not for medical use); toners for scalp (not for medical use). Medicated hair care preparations; medicinal preparations for stimulating hair growth; hair growth stimulants; medicated hair lotions; scalp treatments (Medicated -).
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Cartridges for storing specimen used for DNA analysis apparatus; reagent cartridges used for DNA analysis apparatus; reagent containers used for DNA analysis apparatus; DNA analysis apparatus, not for medical purposes; diagnostic equipments for molecular diagnosis [non-medical]; genetic analyzer, not for medical purposes; gene amplification equipment, not for medical purposes; diagnostic apparatus, not for medical purposes; integrated genetic testing apparatus, not for medical purposes; nucleic acid amplification apparatus for laboratory use; gene analyzing and extracting devices, not for medical purposes; physical analysing apparatus for analysing genes [other than for medical use]; chemical analysing apparatus for analysing genes [other than for medical use]; plate for analyzing genes; genetic probe assay apparatus, not for medical purposes; gene amplifiers; devices for analyzing gene information, not for medical purposes. Medical apparatus and instruments for DNA/RNA analysis; bacteria and virus testing apparatus, for medical and veterinary use; miniaturized sensors for use in gene analysis and diagnosis, for medical and veterinary use; DNA/RNA purification apparatus for medical and veterinary use; genetic testing apparatus for medical and veterinary purposes; medical genetic analyzer for medical and veterinary use; gene amplification apparatus for medical and veterinary use; apparatus for DNA and RNA testing for medical purposes; DNA extraction and purification apparatus for medical purposes; real-time gene amplification equipment for medical use; medical genetic fragment analyzers; diagnostic apparatus for medical use; apparatus for carrying out diagnostic tests for medical purposes; medical diagnostic apparatus and instruments; diagnostic apparatus for medical purposes; automatic molecular diagnosis device of diagnostic and medical use; in vitro diagnostic devices for medical purposes; genetic testing apparatus for in vitro diagnostic use, for medical and veterinary use.
28.
TRACKABLE PRECISE-SAMPLE-INJECTION DEVICE FOR MULTI-WELL PLATE
The present disclosure relates to a trackable precise-sample-injection device for a multi-well plate and, more specifically, to a trackable precise-sample-injection device for a multi-well plate, the device being capable of: preventing cross-contamination that can occur when many samples are manually put into a multi-well plate, and a diagnosis error caused by the injection of a sample into the wrong well or repeated injection; and simply recording and tracking information about wells into which samples are injected. The present disclosure relates to a trackable precise-sample-injection device for a multi-well plate, the device being capable of being efficiently used for a pooling inspection, and the like by injecting a plurality of samples into a multi-well plate.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
29.
COMPOSITION USING URINE SAMPLE FOR DIAGNOSIS OF KIDNEY DISEASE
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (République de Corée)
Inventeur(s)
Son, Seung Seob
Kim, Tae Rim
Lee, Eun Young
Cho, Nam-Jun
Yun, Sung Il
Park, Jun Hong
Park, Han-Oh
Abrégé
The present invention relates to a composition using a urine sample for diagnosis of a kidney disease and, more specifically, to a urine test composition and a kit for diagnosis of a kidney disease, each comprising an agent specifically detecting amphiregulin from a urine sample, and a method for diagnosing a kidney disease by using the composition. According to the present invention, not only is there an advantage of being able to conveniently diagnose a kidney disease in a non-invasive manner using a urine sample for a kidney disease to which early diagnosis is important, but also the application of the present invention to a patient diagnosed with chronic kidney disease can advantageously predict the plausibility of progression into end-stage renal disease in advance.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Beauty creams; beauty masks; cosmetic creams and lotions; cosmetic preparations for hair care; cosmetic preparations for skin care; cosmetic preparations for the hair and scalp; depilatories; depilatory creams; depilatory preparations; face and body beauty creams; face and body creams; face and body lotions; hair care creams; hair care lotions; hair care preparations; hair cleaning preparations; hair colorants; hair conditioner; hair lotions; hair strengthening treatment lotions; lotions for face and body care; make-up preparations for the face and body; shampoos; skin whitening preparations
(2) Hair growth stimulants; medicinal preparations for stimulating hair growth
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
Produits et services
Functional cosmetics; cosmetics for scalp; cosmetic preparations for the hair and scalp; non-medicated scalp stimulating preparations, not for medical use; non-medicated toners for scalp, not for medical use
32.
CTGF GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE, AND A COMPOSITION FOR PREVENTING AND TREATING FIBROTIC DISEASES AND RESPIRATORY-RELATED DISEASES COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide capable of inhibiting CTGF expression with a very specific and high efficiency, a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide, and a use thereof in preventing or treating of fibrotic or respiratory diseases.
H01B 1/02 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisésEmploi de matériaux spécifiés comme conducteurs composés principalement de métaux ou d'alliages
H01B 1/22 - Matériau conducteur dispersé dans un matériau organique non conducteur le matériau conducteur comportant des métaux ou des alliages
B82Y 40/00 - Fabrication ou traitement des nanostructures
34.
ELECTROMAGNETIC SHIELDING COMPOSITION CONTAINING MORPHOLOGICALLY DIFFERENT METALS
An electromagnetic shielding composition according to the present invention is directed to an electromagnetic shielding composition capable of forming an electromagnetic shielding film with excellent electromagnetic shielding capacity and flexibility and, specifically, comprises: a core-shell structured metal nanowire comprising a core containing copper and a shell containing silver on the core; and plate-like metal particles selected from plate-like silver particles and silver-coated plate-like copper particles.
A conductive paste composition according to the present disclosure contains silver-coated copper nanowires with a core-shell structure; a binder mixture containing a silicone resin binder and a hydrocarbon-based resin binder; and an organic solvent, such that the conductive paste composition has a low sheet resistance and may withstand a high temperature, thereby implementing excellent conductivity and electromagnetic wave shielding properties. Furthermore, the conductive paste may be widely used in various fields such as electromagnetic wave shielding, solar cell electrodes, electronic circuits, and antennas.
Provided is an electric grill capable of precisely controlling the temperature of a grilling plate by directly applying a heating paste including carbon nanotubes to the bottom of the grilling plate. The present invention includes the grilling plate on which food to be cooked is placed; a heating body that is applied so as to be arranged on the lower portion of the grilling plate so as to heat the grilling plate; a heat insulating material which is disposed to be spaced apart from the heating body at a predetermined distance so as to block heat conduction to the outside; and a temperature sensor which is disposed between the heating body and the heat insulating material so as to measure the temperature of an upper plate. A pair of electrodes for supplying electricity to the heating body are arranged along opposite edges of both sides of the heating body, and a heating region can be divided and controlled by dividing and combining the pair of electrodes, the heating body, the coating thickness, and the like.
H05B 3/26 - Éléments chauffants ayant une surface s'étendant essentiellement dans deux dimensions, p. ex. plaques chauffantes non flexibles le conducteur chauffant monté sur une base isolante
17 - Produits en caoutchouc ou en matières plastiques; matières à calfeutrer et à isoler
Produits et services
Silicone based sealants and adhesives
38.
COMPOSITION FOR ADMINISTRATION OF DOUBLE-STRANDED OLIGONUCLEOTIDE STRUCTURES USING ULTRASONIC NEBULIZER FOR PREVENTION OR TREATMENT OF RESPIRATORY VIRAL INFECTION INCLUDING COVID-19, PULMONARY FIBROSIS CAUSED BY VIRAL INFECTION, OR RESPIRATORY DISEASES
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Han-Oh
Lee, Sang-Kyu
Yun, Sung-Il
Kwon, Oh Seung
Goh, Eun-Ah
Goh, Young-Ho
Park, Jun-Hong
Song, Kang
Kim, Jangseon
Lee, Mi-Sun
Choi, Soon-Ja
Abrégé
The present invention relates to a composition for administering a double-stranded oligonucleotide structure using an ultrasonic nebulizer. According to the method, the double-stranded oligonucleotide according to the present invention forms self-assembled nanoparticles, which are 90 nm in size and have a neutral charge, and it is possible to deliver the double-stranded oligonucleotide specifically to the nasal cavity and lungs while maintaining not only the same concentration, molecular weight, purity, nanoparticle size, and osmolality as those of the stock material but also the target gene inhibitory activity without cytotoxicity. Thus, the present invention may be useful for the prevention or treatment of respiratory viral infections including COVID-19, pulmonary fibrosis caused by viral infection, or respiratory diseases.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
39.
COMPOSITION FOR ADMINISTRATION OF DOUBLE-STRANDED OLIGONUCLEOTIDE STRUCTURES USING ULTRASONIC NEBULIZER FOR PREVENTION OR TREATMENT OF RESPIRATORY VIRAL INFECTION INCLUDING COVID-19, PULMONARY FIBROSIS CAUSED BY VIRAL INFECTION, OR RESPIRATORY DISEASES
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Han-Oh
Lee, Sang-Kyu
Yun, Sung-Il
Kwon, Oh Seung
Goh, Eun-Ah
Goh, Young-Ho
Park, Jun-Hong
Song, Kang
Kim, Jangseon
Lee, Mi-Sun
Choi, Soon-Ja
Abrégé
The present invention relates to a composition for administering a double-stranded oligonucleotide structure using an ultrasonic nebulizer. The method allows the double-stranded oligonucleotide, according to the present invention, which forms self-assembled nanoparticles having a neutral charge of 90 nm in an aqueous solution, to maintain the same concentration, molecular weight, purity, nanoparticle size, and osmolality as the undiluted solution material. In addition, the method can maintain target gene suppression ability without cytotoxicity and can deliver drugs specifically to the nasal cavity and lungs, thus allowing the present invention to be utilized in the prevention or treatment of respiratory viral infections including COVID-19, pulmonary fibrosis caused by viral infections, or respiratory diseases.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
40.
COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT
The present invention relates to a composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded miRNA as an active ingredient and, more specifically, to: miR-3139, miR-3189, miR-3199 or miR-8485, which are double-stranded miRNA; a double-stranded oligonucleotide structure comprising same; or a pharmaceutical or cosmetic composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising nanoparticles containing the structure as an active ingredient. A composition according to the present invention can prevent hair graying and reduce the rate of progress thereof by activating melanocytes and promoting melanogenesis and can allow the hair already affected by graying to be improved to a state before graying. In addition, the composition promotes the activation of melanocytes and the proliferation of dermal papilla cells and keratinocytes that are present in hair follicles, and induces outer root sheath development and hair growth so that the effects of promoting hair growth and/or preventing hair loss can be exhibited.
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
41.
COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Han-Oh
Lee, Sang-Kyu
Kwon, Oh Seung
Goh, Eun-Ah
Abrégé
The present invention relates to a composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded miRNA as an active ingredient and, more specifically, to: miR-3139, miR-3189, miR-3199 or miR-8485, which are double-stranded miRNA; a double-stranded oligonucleotide structure comprising same; or a pharmaceutical or cosmetic composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising nanoparticles containing the structure as an active ingredient. A composition according to the present invention can prevent hair graying and reduce the rate of progress thereof by activating melanocytes and promoting melanogenesis and can allow the hair already affected by graying to be improved to a state before graying. In addition, the composition promotes the activation of melanocytes and the proliferation of dermal papilla cells and keratinocytes that are present in hair follicles, and induces outer root sheath development and hair growth so that the effects of promoting hair growth and/or preventing hair loss can be exhibited.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
functional cosmetics; cosmetics for scalp; hair strengthening treatment lotions; hair stabilizers; hair care agents; hair lotions; hair care preparations; hair conditioner; hair care lotions; hair care creams; cosmetic preparations for hair care; hair essences; hair essence mists; beauty creams; cosmetic preparations for skin care; face and body lotions; make-up preparations for the face and body; face and body beauty creams; lotions for face and body care; cosmetic creams and lotions; face and body creams; shampoo; beauty masks; hair colorants; colouring preparations for cosmetic purposes; skin whitening preparations; hair cleaning preparations; cosmetic preparations for the hair and scalp; depilatory creams; depilatory preparations; depilatories; scalp stimulating preparations (not for medical use); toners for scalp (not for medical use). medicated hair care preparations; medicinal preparations for stimulating hair growth; hair growth stimulants; medicated hair lotions; scalp treatments (Medicated -).
43.
ADAPTER FOR MOUNTING CONDUCTIVE PIPETTE, SAMPLE TUBE OPENING/CLOSING DEVICE, AND AUTOMATIC SAMPLE ANALYSIS SYSTEM
The present invention relates to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system and, more specifically, to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system, in which dispensing of a liquid sample and extraction, amplification and testing of nucleic acids are integrally carried out. In the present invention, disclosed is a sample tube opening/closing device comprising: a housing (110) that forms an inner space isolated from the outside and includes a door (120) for moving in/out a multi-well plate (20) for biological samples, including a plurality of sample tubes (10) in which biological samples are accommodated; and a sample tube opening/closing part that is installed in the inner space to be spaced apart from the multi-well plate (20) for biological samples and automatically opens and closes the sample tubes (10).
The present invention relates to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system and, more specifically, to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system, in which dispensing of a liquid sample and extraction, amplification and testing of nucleic acids are integrally carried out. In the present invention, disclosed is a sample tube opening/closing device comprising: a housing (110) that forms an inner space isolated from the outside and includes a door (120) for carrying in/out a multi-well plate (20) for biological samples, including a plurality of sample tubes (10) in which biological samples are accommodated; and a sample tube opening/closing part that is installed in the inner space to be spaced apart from the multi-well plate (20) for biological samples and automatically opens and closes the sample tubes (10).
The present invention relates to a system structure capable of performing real-time detection of nucleic acid extraction and amplification reactions and amplified results in a device for implementing a polymerase chain reaction (PCR). A PCR system includes a nucleic acid extraction cartridge configured to extract a nucleic acid of a biological sample via a nucleic acid extraction reagent stored therein and form a PCR preliminary mixture by being additionally mixed with a polymerase reaction dried product, a PCR plate inserted into the nucleic acid extraction cartridge, having a channel coupled to the nucleic acid extraction cartridge, and receives a nucleic acid solution or the PCR preliminary mixture extracted from the nucleic acid extraction cartridge and diversely accommodates a PCR reaction dried product containing a dried primer/probe or a primer/probe in at least one reaction well, a temperature control module disposed above the PCR plate 200 and including a pair of heating blocks 310 and 320 adjacent to the reaction well (W) to apply different temperatures, and a scanning module scanning a concentration of a reactant amplified in the reaction well (W).
The present invention relates to a method for isolating a nucleic acid by using: a binding buffer containing acetic acid or phosphoric acid; and the pH difference between binding and washing buffers, and an elution buffer, wherein silica magnetic particles are added to a biological sample including a nucleic acid to which a binding buffer containing acetic acid, phosphoric acid, etc., has been added, thereby binding the nucleic acid to the magnetic particles, after which a magnetic field is applied to separate the magnetic particles, and the nucleic acid is purified in a basic pH elution buffer. The method uses the pH difference, and can isolate the nucleic acid more quickly and efficiently than centrifugation or gravity separation. In addition, since ethanol is not used, high-purity nucleic acid can be isolated and purified to obtain more accurate results in subsequent experiments.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
47.
Double stranded oligonucleotide construct comprising androgen receptor specific sequence, and composition for preventing hair loss and promoting hair growth comprising same
Disclosed are a double stranded oligonucleotide construct, configured such that a hydrophilic material and a hydrophobic material are conjugated through a simple covalent bond or a linker-mediated covalent bond to both ends of a double stranded oligonucleotide in order to efficiently deliver an androgen-receptor-specific oligonucleotide into a cell, a nanoparticle capable of being produced by self-assembling double stranded oligonucleotide constructs in an aqueous solution through hydrophobic interactions, and a composition for preventing hair loss or promoting hair growth containing the double stranded oligonucleotide construct. The double stranded oligonucleotide construct including the androgen-receptor-specific oligonucleotide and the composition for preventing hair loss or promoting hair growth containing the same as an active ingredient can suppress the expression of an androgen receptor with high efficiency without side effects, and can thus exhibit excellent effects on preventing hair loss, particularly androgenetic alopecia, alopecia areata, and telogen effluvium, and promoting hair growth.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 8/84 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61Q 7/00 - Préparations pour modifier la pousse des cheveux ou des poils
48.
NUCLEIC ACID AMPLIFICATION TEST APPARATUS, AND AUTOMATIC SAMPLE ANALYSIS SYSTEM HAVING SAME
The present invention relates to a nucleic acid amplification test apparatus, and an automatic sample analysis system having same and, more particularly, to a nucleic acid amplification test apparatus in which separation and purification, dispensation, amplification, and testing of samples are performed integrally, and an automatic sample analysis system having same. Disclosed in the present invention is a nucleic acid amplification test apparatus comprising: a housing (30) having an inner space (S1) isolated from the outside; a multi-well plate insertion unit (100) into which a multi-well plate (40) having a plurality of reaction tubes (1) accommodating a target nucleic acid solution is inserted through an automatic purification and dispensing apparatus (10); a sealing plate insertion unit (200) into which a sealing plate (50) having a sealing means for sealing the inlets of the plurality of reaction tubes (1); a fluorescence detection unit (400) disposed on an upper side of the sealing plate insertion unit (200) and detecting a target nucleic acid in the reaction tubes (1); and a temperature control block (500) disposed on a lower side of the multi-well plate insertion unit (100) and controlling the temperature of the reaction tubes (1), wherein the reaction tubes (1) are moved relatively so as to be adjacent to the sealing means to be then sealed by the sealing means.
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
49.
NUCLEIC ACID AMPLIFICATION TEST APPARATUS, AND AUTOMATIC SAMPLE ANALYSIS SYSTEM HAVING SAME
The present invention relates to a nucleic acid amplification test apparatus, and an automatic sample analysis system having same and, more particularly, to a nucleic acid amplification test apparatus in which separation and purification, dispensation, amplification, and testing of samples are performed integrally, and an automatic sample analysis system having same. Disclosed in the present invention is a nucleic acid amplification test apparatus comprising: a housing (30) having an inner space (S1) isolated from the outside; a multi-well plate insertion unit (100) into which a multi-well plate (40) having a plurality of reaction tubes (1) accommodating a target nucleic acid solution is inserted through an automatic purification and dispensing apparatus (10); a sealing plate insertion unit (200) into which a sealing plate (50) having a sealing means for sealing the inlets of the plurality of reaction tubes (1); a fluorescence detection unit (400) disposed on an upper side of the sealing plate insertion unit (200) and detecting a target nucleic acid in the reaction tubes (1); and a temperature control block (500) disposed on a lower side of the multi-well plate insertion unit (100) and controlling the temperature of the reaction tubes (1), wherein the reaction tubes (1) are moved relatively so as to be adjacent to the sealing means to be then sealed by the sealing means.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
50.
DOUBLE-STRANDED OLIGONUCLEOTIDE TARGETING DKK1 GENE, CONSTRUCT INCLUDING SAME, AND HAIR LOSS PREVENTION OR HAIR GROWTH COMPOSITION CONTAINING SAME
The present invention pertains to: a double-stranded oligonucleotide construct having a structure in which a hydrophilic substance and a hydrophobic substance are conjugated by a simple covalent bond or a linker-mediated covalent bond at both ends of a DKK1-specific double-stranded oligonucleotide to efficiently deliver the double-stranded oligonucleotide into cells; a nanoparticle capable of being produced through self-assembly of the double-stranded oligonucleotide construct through a hydrophobic interaction in an aqueous solution; and a hair-loss-preventing and hair-growth-promoting composition containing the double-stranded oligonucleotide construct or the nanoparticle. A double-stranded oligonucleotide construct including a DKK1-specific double-stranded oligonucleotide, a nanoparticle, and a hair loss prevention or hair growth composition containing the double-stranded oligonucleotide construct or the nanoparticle as an active ingredient according to the present invention very efficiently suppress the expression of DKK1 without side effects and are remarkably effective for preventing hair loss and promoting hair growth, and can thus be very usefully used for a composition for preventing hair loss and promoting hair growth.
A heater integrated gas chromatography (GC) column device according to the present invention is capable of precisely and uniformly controlling a temperature by having a high thermal conductivity, and raising and lowering a temperature at a high speed by having a low thermal mass, such that a measuring time is significantly decreased. The GC column is in contact with a bobbin with a homogeneous temperature distribution, and thus a temperature is homogeneously distributed in each GC column. Further, the heater integrated GC column device according to the present invention has the above-described effects and may have a smaller size.
H05B 3/14 - Éléments chauffants caractérisés par la composition ou la nature des matériaux ou par la disposition du conducteur caractérisés par la composition ou la nature du matériau conducteur le matériau étant non métallique
A sample concentrator tube having a heat-resistant planar heating element adhered thereto, an analysis device comprising the same, and an analysis method using the same, according to the present invention, have an effect capable of precisely controlling the temperature by uniformly and rapidly heating the sample concentrator tube to a target temperature for desorption, and capable of almost simultaneously desorbing an adsorbed sample in any part of an adsorbent by minimizing a local temperature difference of the adsorbent in the tube. In addition, it is possible to minimize chemical noise by preventing thermal denaturation of the adsorbent caused by over-heating, and there is an advantage of excellent reproducibility as well as an effect of being inexpensive, economical, and excellent in energy efficiency.
G01N 1/44 - Traitement d'échantillons mettant en œuvre un rayonnement, p. ex. de la chaleur
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
H05B 3/26 - Éléments chauffants ayant une surface s'étendant essentiellement dans deux dimensions, p. ex. plaques chauffantes non flexibles le conducteur chauffant monté sur une base isolante
H05B 3/46 - Éléments chauffants ayant la forme de tiges ou de tubes non flexibles le conducteur chauffant monté sur une base isolante
H05B 3/06 - Éléments chauffants combinés constructivement avec des éléments d'accouplement ou avec des supports
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
53.
PROBE HAVING OCTAMINE OR OCTAMINE DERIVATIVE BOUND THERETO, AND USES OF SAME
The present invention relates to a probe having octamine or octamine derivative bound thereto in addition to a reporter and a quencher to thus allow the quencher to more effectively suppress light emitted by the reporter, and to uses of the probe. When the probe according to the present invention is utilized, octamine or octamine derivative bound to the probe effectively suppresses the light emitted by the quencher for the reporter, and results in effects such as i) a reduction in base fluorescence, ii) an increase in delta fluorescence, and iii) a decrease in the value of cycle at threshold, thus allowing the probe to be effectively used in a variety of real-time polymerase chain reactions requiring accuracy and sensitivity.
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Han-Oh
Kim, Jangseon
Lee, Mi Sun
Choi, Soonja
Lee, Eun-Kwang
Byun, Sang Jin
Abrégé
The present invention relates to: a double-stranded oligonucleotide which can highly specifically and efficiently inhibit the proliferation of Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), preferably a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or a DNA/RNA hybrid; a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide; and a use thereof for treating COVID-19.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61P 31/14 - Antiviraux pour le traitement des virus ARN
55.
COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASE CONTAINING AMPHIREGULIN-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE STRUCTURE
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
Inventeur(s)
Park, Jun Hong
Park, Han-Oh
Yun, Sung Il
Kim, Tae Rim
Hwang, Soo Hyun
Song, Kang
Jung, Sang Hyuk
Kim, Jangseon
Lee, Mi Sun
Choi, Soonja
Son, Seung-Seob
Abrégé
The present invention relates to: a double-stranded oligonucleotide which can highly specifically and efficiently inhibit amphiregulin expression, preferably a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or a DNA/RNA hybrid; and a use, of a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide, for preventing or treating obesity.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
The present invention relates to a double-stranded oligonucleotide capable of inhibiting amphiregulin expression in a very specific and highly efficient manner, preferably a double-stranded oligonucleotide comprising a sequence in the form of an RNA/RNA, DNA/DNA or DNA/RNA hybrid, and the use of a double-stranded oligonucleotide structure, which comprises the double-stranded oligonucleotide, and nanoparticles, for preventing or treating obesity.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
The present invention relates to a trackable precise-sample-injection device for a multi-well plate and, more specifically, to a trackable precise-sample-injection device for a multi-well plate, the device being capable of: preventing cross-contamination that can occur when many samples are manually put into a multi-well plate, and a diagnosis error caused by the injection of a sample into the wrong well or repeated injection; and simply recording and tracking information about wells into which samples are injected. The present invention relates to a trackable precise-sample-injection device for a multi-well plate, the device being capable of being efficiently used for a pooling inspection, and the like by injecting a plurality of samples into a multi-well plate.
SIRNAGEN THERAPEUTICS CORPORATION (République de Corée)
SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (République de Corée)
Inventeur(s)
Son, Seung Seob
Kim, Tae Rim
Yun, Sung Il
Park, Jun Hong
Park, Han-Oh
Cho, Nam-Jun
Lee, Eun Young
Abrégé
The present invention relates to a composition using a urine sample for diagnosis of a kidney disease and, more specifically, to a urine test composition and a kit for diagnosis of a kidney disease, each comprising an agent specifically detecting amphiregulin from a urine sample, and a method for diagnosing a kidney disease by using the composition. According to the present invention, not only is there an advantage of being able to conveniently diagnose a kidney disease in a non-invasive manner using a urine sample for a kidney disease to which early diagnosis is important, but also the application of the present invention to a patient diagnosed with chronic renal failure can advantageously predict the plausibility of progression into end-stage renal failure in advance.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
59.
Target material extraction apparatus with replacement of magnetic bar block allowed
The present invention relates to an extraction apparatus capable of simultaneously extracting target materials from multiple biological samples and, more particularly, to a target material extraction apparatus in which magnetic bar blocks can be replaced according to kinds of multi-well plates to be inserted into a cartridge. When used, the target material extraction apparatus of the present invention is operated in such a manner that among various plates multi-well having different numbers of wells, multi-well plates suitable for a use purpose are loaded into a cartridge within the apparatus and magnetic bar blocks equipped with magnetic bars suitable therefor are selected and loaded. Thus, the apparatus has the advantage of selectively applying various multi-well plates to one installment according to the number of samples from which a target material is extracted or to the amount of the target material to be extracted.
The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
C07K 14/335 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Lactobacillus (G)
An electric roasting pan according to the present invention comprises: a roasting pan; a heating layer being in surface contact with the roasting pan and comprising a carbon nanotube and a silicone-based adhesive; and an electrode in contact with the heating layer. The electric roasting pan has excellent thermal efficiency thanks to the minimal heat loss thereof, can reach a target temperature within a short time to reduce a preheating time, and affords excellent cooking quality. Furthermore, the electric roasting pan can substantially prevent the occurrence of temperature deviation across the area of the roasting pan during a temperature increase and is of high durability and safety.
H05B 3/14 - Éléments chauffants caractérisés par la composition ou la nature des matériaux ou par la disposition du conducteur caractérisés par la composition ou la nature du matériau conducteur le matériau étant non métallique
A47J 36/04 - Emploi de matériaux spécifiés, p. ex. double-fonds avec une plaque de cuivre ou une plaque isolante les matériaux n'étant pas métalliques
A47J 37/10 - Poêles à frire, p. ex. poêles à frire avec couvercles ou dispositifs d'arrosage intégrés
H05B 1/02 - Dispositions de commutation automatique spécialement adaptées aux appareils de chauffage
62.
CTGF GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE, AND A COMPOSITION FOR PREVENTING AND TREATING FIBROTIC DISEASES AND RESPIRATORY-RELATED DISEASES COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide capable of inhibiting CTGF expression with a very specific and high efficiency, a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide, and a use thereof in preventing or treating of fibrotic or respiratory diseases.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
63.
CTGF GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE, AND A COMPOSITION FOR PREVENTING AND TREATING FIBROTIC DISEASES AND RESPIRATORY-RELATED DISEASES COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide capable of inhibiting CTGF expression with a very specific and high efficiency, a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide, and a use thereof in preventing or treating of fibrotic or respiratory diseases.
The present invention relates to an electric grill capable of precisely controlling the temperature of a grilling plate by directly applying a heating paste including carbon nanotubes to the bottom of the grilling plate. The present invention comprises: the grilling plate on which food to be cooked is placed; a heating body that is applied so as to be arranged on the lower portion of the grilling plate so as to heat the grilling plate; a heat insulating material which is disposed to be spaced apart from the heating body at a predetermined distance so as to block heat conduction to the outside; and a temperature sensor which is disposed between the heating body and the heat insulating material so as to measure the temperature of an upper plate, wherein a pair of electrodes for supplying electricity to the heating body are arranged along opposite edges of both sides of the heating body, and a heating region can be divided and controlled by dividing and combining the pair of electrodes, the heating body, the coating thickness, and the like.
H05B 3/16 - Éléments chauffants caractérisés par la composition ou la nature des matériaux ou par la disposition du conducteur le conducteur étant monté sur une base isolante
65.
CONDUCTIVE PASTE COMPOSITION COMPRISING SILVER-COATED COPPER NANOWIRE WITH CORE-SHELL STRUCTURE AND CONDUCTIVE FILM COMPRISING SAME
A conductive paste composition according to the present invention comprises: a silver-coated copper nanowire with a core-shell structure; a binder mixture containing a silicone resin binder and a hydrocarbon-based resin binder; and an organic solvent, and thus has low sheet resistance and can endure high temperatures, thereby achieving excellent conductivity and electromagnetic wave shielding characteristics. Furthermore, the conductive paste can be easily manufactured into a planar conductive film through a simple process, and the conductive film can be widely used in various fields, such as electromagnetic wave shielding, solar cell electrodes, electronic circuits, antennas, and the like.
H01B 1/22 - Matériau conducteur dispersé dans un matériau organique non conducteur le matériau conducteur comportant des métaux ou des alliages
H01B 5/14 - Conducteurs ou corps conducteurs non isolés caractérisés par la forme comprenant des couches ou pellicules conductrices sur supports isolants
C08L 33/00 - Compositions contenant des homopolymères ou des copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et un seul étant terminé par un seul radical carboxyle, ou ses sels, anhydrides, esters, amides, imides ou nitrilesCompositions contenant des dérivés de tels polymères
The present invention relates to the structure of an analysis plate applied to a high-speed polymerase chain reaction (PCR), and to a PCR analysis plate used for implementing an analysis of a real-time PCR, a real-time nested PCR and a post-PCR lateral flow hybridization reaction. The present invention is provided with: a check valve for enabling the maintaining of positive pressure when an elastic film expands into a convex form by having a solution pushed therein by the positive pressure; a lateral flow analysis module for analyzing a post-PCR follow-up PCR or lateral flow; and a shut-off valve enabling the controlling of the movement of the solution after each reaction ends. A high-speed PCR analysis plate may be provided whereby, by pressing, by means of a temperature-controllable heating block, the elastic film, which is in a convex form by the solution, of a PCR unit, a PCR solution may undergo rapid temperature circulation with minimum heat resistance, and a PCR dried material and a nucleic acid solution may be homogenized and mixed.
The present invention relates to a double-helix oligonucleotide construct comprising a double-stranded miRNA and a composition for preventing or treating cancer comprising the same. More particularly, the present invention relates to a double-helix oligonucleotide construct comprising miR-544a characterized by a method that effectively inhibits the proliferation of cancer cells or induces a voluntary death of cancer cells, and an anticancer composition comprising the construct.
The present invention relates to a system structure capable of detecting, in real time, nucleic acid extraction and amplification reactions and amplified products in an apparatus for implementing a polymerase chain reaction, the system structure comprising: a nucleic acid extraction cartridge for extracting nucleic acids from a biological sample with a nucleic acid extraction reagent stored therein, or preparing a PCR premix by additionally mixing the nucleic acids with a dried product of the polymerase chain reaction; a PCR plate which is inserted into the nucleic acid extraction cartridge and coupled thereto such that a flow path is connected therebetween, and which receives a nucleic acid solution or a PCR premix, which is extracted from the nucleic acid extraction cartridge, and dispenses and accommodates same in at least one reaction well having accommodated therein dried primers/probes, or a dried PCR product comprising primers/probes; a temperature control module provided on the PCR plate and comprising a pair of heating blocks which are adjacent to the reaction well (W) and apply different temperatures; and a scanning module provided below the PCR plate to scan the concentration of a reaction product amplified in the reaction well (W).
A bio sample collection device including: a housing; a cap part detachably fastened to the housing, and including a bio sample collector for collecting a bio sample; and a bio sample processing liquid storage unit storing bio sample processing liquid, the bio sample processing liquid storage unit being formed to be broken when the cap part is combined with the housing after bio sample is collected so that the bio sample processing liquid is mixed with the bio sample.
The present invention pertains to: a double-stranded oligonucleotide construct having a structure in which a hydrophilic substance and a hydrophobic substance are conjugated by a simple covalent bond or a linker-mediated covalent bond at both ends of a DKK1-specific double-stranded oligonucleotide to efficiently deliver the double-stranded oligonucleotide into cells; a nanoparticle which can be produced through self-assembly of the double-stranded oligonucleotide construct by a hydrophobic interaction in an aqueous solution; and a hair loss-preventing and hair growth-promoting composition containing the double-stranded oligonucleotide construct or the nanoparticle. A double-stranded oligonucleotide construct including a DKK1-specific double-stranded oligonucleotide; a nanoparticle; and a hair loss prevention or hair growth composition containing the double-stranded oligonucleotide construct or the nanoparticle as an active ingredient according to the present invention highly efficiently suppress the expression of DKK1 without side effects, and are remarkably effective for preventing hair loss and promoting hair growth, and can thus be very usefully used for a composition for preventing hair loss and promoting hair growth.
A sample concentrator tube having a heat-resistant planar heating element adhered thereto, an analysis device comprising same, and an analysis method using same, according to the present invention, have an effect capable of precisely controlling the temperature by heating the sample concentrator tube uniformly and rapidly to a target temperature for desorption, and of desorbing an adsorbed sample almost simultaneously in any part of an adsorbent by minimizing the local temperature difference of the adsorbent in the tube. In addition, it is possible to minimize chemical noise by preventing thermal denaturation of the adsorbent caused by overheating, and there is an advantage of excellent reproducibility as well as an effect of being inexpensive, economical, and excellent in energy efficiency.
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
H05B 3/20 - Éléments chauffants ayant une surface s'étendant essentiellement dans deux dimensions, p. ex. plaques chauffantes
H05B 3/40 - Éléments chauffants ayant la forme de tiges ou de tubes
72.
HEATER INTEGRATED GAS CHROMATOGRAPHY COLUMN DEVICE
A heater integrated gas chromatography (GC) column device according to the present invention is capable of precisely and uniformly controlling a temperature by having a high thermal conductivity, and raising and lowering a temperature at a high speed by having a low thermal mass, such that a measuring time is significantly decreased. The GC column is in contact with a bobbin with a homogeneous temperature distribution, and thus a temperature is homogeneously distributed in each GC column. Further, the heater integrated GC column device according to the present invention has the above-described effects and may have a smaller size.
G01N 30/30 - Contrôle des paramètres physiques du fluide vecteur de la température
H05B 3/16 - Éléments chauffants caractérisés par la composition ou la nature des matériaux ou par la disposition du conducteur le conducteur étant monté sur une base isolante
H05B 3/14 - Éléments chauffants caractérisés par la composition ou la nature des matériaux ou par la disposition du conducteur caractérisés par la composition ou la nature du matériau conducteur le matériau étant non métallique
a and miR-8078, and characterized by a method for effectively inhibiting cancer cell proliferation or inducing cancer cell apoptosis; and a pharmaceutically acceptable carrier.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 31/25 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques avec des alcools polyoxyalkylés, p. ex. esters de polyéthylèneglycol
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
74.
DOUBLE STRANDED OLIGONUCLEOTIDE CONSTRUCT COMPRISING ANDROGEN RECEPTOR SPECIFIC SEQUENCE, AND COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING SAME
The present invention relates to: a double stranded oligonucleotide construct having a structure of the form in which a hydrophilic material and a hydrophobic material are conjugated by a simple covalent bond or a linker-mediated covalent bond at both ends of a double stranded oligonucleotide in order to efficiently deliver an androgen receptor specific oligonucleotide into a cell; a nanoparticle which can be produced by self-assembling the double stranded oligonucleotide constructs in an aqueous solution by hydrophobic interaction; and a composition for preventing hair loss or for promoting hair growth comprising the double stranded oligonucleotide construct. The double stranded oligonucleotide construct comprising an androgen receptor specific oligonucleotide, and the composition for preventing hair loss or for promoting hair growth comprising the same as an active ingredient, according to the present invention, can inhibit the expression of an androgen receptor with high efficiency without side effects, and thus can have an excellent effect on the prevention of hair loss, especially androgenic hair loss, alopecia areata, and telogen alopecia and the promotion of hair growth.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
75.
DOUBLE STRANDED OLIGONUCLEOTIDE CONSTRUCT COMPRISING ANDROGEN RECEPTOR SPECIFIC SEQUENCE, AND COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING SAME
A double stranded oligonucleotide construct having a structure of Structural Formula (1): A-X-R-Y-B Structural Formula (1), is provided for preventing hair loss or promoting hair growth. In Structural Formula (1), wherein A is a hydrophilic material, B is a hydrophobic material, each of X and Y independently represents a covalent bond or a linker-mediated covalent bond, and R represents an androgen-receptor-specific oligonucleotide comprising a sense strand comprising SEQ ID NO: 68 or 109 and an antisense strand comprising a sequence complementary thereto.
A61K 8/81 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons insaturées carbone-carbone
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
76.
PROBE HAVING OCTAMINE OR OCTAMINE DERIVATIVE BOUND THERETO, AND USES OF SAME
The present invention relates to a probe having octamine or octamine derivative bound thereto in addition to a reporter and a quencher to thus allow the quencher to more effectively suppress light emitted by the reporter, and to uses of the probe. When the probe according to the present invention is utilized, octamine or octamine derivative bound to the probe effectively suppresses the light emitted by the quencher for the reporter, and results in effects such as i) a reduction in base fluorescence, ii) an increase in delta fluorescence, and iii) a decrease in the value of cycle at threshold, thus allowing the probe to be effectively used in a variety of real-time polymerase chain reactions requiring accuracy and sensitivity.
The present invention relates to an epoxy paste composition including silver-coated copper nanowires having a core-shell structure, and a conductive film including the same.
H01B 1/22 - Matériau conducteur dispersé dans un matériau organique non conducteur le matériau conducteur comportant des métaux ou des alliages
B32B 5/16 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par le fait qu'une des couches est formée de particules, p. ex. de copeaux, de fibres hachées, de poudre
H01B 1/02 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisésEmploi de matériaux spécifiés comme conducteurs composés principalement de métaux ou d'alliages
C08K 9/02 - Ingrédients traités par des substances inorganiques
The present invention relates to an extraction apparatus capable of simultaneously extracting target materials from multiple biological samples and, more particularly, to a target material extraction apparatus in which magnetic bar blocks can be replaced according to kinds of multi-well plates to be inserted into a cartridge. When used, the target material extraction apparatus of the present invention is operated in such a manner that among various multi-well plates having different numbers of wells, multi-well plates suitable for a use purpose are loaded into a cartridge within the apparatus and magnetic bar blocks equipped with magnetic bars suitable therefor are selected and loaded. Thus, the apparatus has the advantage of selectively applying various multi-well plates to one installment according to the number of samples from which a target material is extracted or to the amount of the target material to be extracted.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
79.
Highly active silica magnetic nanoparticles for purifying biomaterial and preparation method thereof
The present invention relates to a method for preparing highly active silica magnetic nanoparticles, highly active silica magnetic nanoparticles prepared by the method, and a method of isolating nucleic acid using the highly active silica magnetic nanoparticles. The highly active silica magnetic nanoparticles prepared according to the present invention contain magnetic nanoparticles completely coated with silica, can be used as a reagent for isolating biomaterials, particularly, nucleic acids, and can isolate and purify nucleic acid in a high yield.
H01F 1/06 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité en matériaux magnétiques durs métaux ou alliages sous forme de particules, p. ex. de poudre
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
H01F 1/00 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques
C01B 33/18 - Préparation de silice finement divisée ni sous forme de sol ni sous forme de gelPost-traitement de cette silice
80.
Sample plate for MALDI mass spectrometry and manufacturing method therefor
A sample plate for MALDI mass spectrometry, according to the present invention, enables separately positioning, by means of a plastic insulation plate, metal wiring and metal dots onto which an analyte sample is to be loaded, and electrically connecting same by means of a via or a metal portion, and thus the energy transferred into the plate when radiating a laser beam on the target (metal dots) may be reduced compared to a sample plate using a base metal, and thus laser energy may be concentrated on the target, and an effect may be achieved whereby heat loss is minimized.
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
The present invention relates to an ion guide for transferring ions to a mass spectrometer. The ion guide of the present invention is characterized in that a plurality of DC rings and a plurality of RF multi-pole rings with a plurality of electrodes are arranged so as to intersect with each other between an inlet into which the ions move and an outlet for transferring the ions, wherein the inner diameter of the DC rings is kept constant and the inner diameter of the RF multi-pole rings gradually decreases in a direction from the inlet to the outlet.
An electric roasting pan according to the present invention comprises: a roasting pan; a heating layer being in surface contact with the roasting pan and comprising a carbon nanotube and a silicone-based adhesive; and an electrode in contact with the heating layer. The electric roasting pan has excellent thermal efficiency thanks to the minimal heat loss thereof, can reach a target temperature within a short time to reduce a preheating time, and affords excellent cooking quality. Furthermore, the electric roasting pan can substantially prevent the occurrence of temperature deviation across the area of the roasting pan during a temperature increase and is of high durability and safety.
A47J 37/10 - Poêles à frire, p. ex. poêles à frire avec couvercles ou dispositifs d'arrosage intégrés
A47J 36/02 - Emploi de matériaux spécifiés, p. ex. double-fonds avec une plaque de cuivre ou une plaque isolante
H05B 3/14 - Éléments chauffants caractérisés par la composition ou la nature des matériaux ou par la disposition du conducteur caractérisés par la composition ou la nature du matériau conducteur le matériau étant non métallique
H05B 3/20 - Éléments chauffants ayant une surface s'étendant essentiellement dans deux dimensions, p. ex. plaques chauffantes
83.
AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide which can highly specifically and efficiently inhibit an amphiregulin expression and, preferably, a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or DNA/RNA hybrid, a double-stranded oligonucleotide structure comprising the double-stranded oligonucleotide, nanoparticles comprising the double-stranded oligonucleotide structure, and a fibrosis or respiratory disease preventive or therapeutic use thereof.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
84.
AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION, FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide which can highly specifically and efficiently inhibit an amphiregulin expression and, preferably, a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or DNA/RNA hybrid, a double-stranded oligonucleotide structure comprising the double-stranded oligonucleotide, nanoparticles comprising the double-stranded oligonucleotide structure, and a fibrosis or respiratory disease preventive or therapeutic use thereof.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to the structure of an analysis plate applied to a high-speed polymerase chain reaction (PCR), and to a PCR analysis plate used for implementing an analysis of a real-time PCR, a real-time nested PCR and a post-PCR lateral flow hybridization reaction. The present invention is provided with: a check valve for enabling the maintaining of positive pressure when an elastic film expands into a convex form by having a solution pushed therein by the positive pressure; a lateral flow analysis module for analyzing a post-PCR follow-up PCR or lateral flow; and a shut-off valve enabling the controlling of the movement of the solution after each reaction ends. A high-speed PCR analysis plate may be provided whereby, by pressing, by means of a temperature-controllable heating block, the elastic film, which is in a convex form by the solution, of a PCR unit, a PCR solution may undergo rapid temperature circulation with minimum heat resistance, and a PCR dried material and a nucleic acid solution may be homogenized and mixed.
The present invention relates to a matrix-assisted laser desorption ionization mass spectrometry method and, specifically, a mass spectrometry method according to the present invention comprises the steps of: acquiring a mass spectrum of an analyte by performing matrix-assisted laser desorption ionization of the analyte, wherein a detection spectrum, which is the mass spectrum of the analyte, is acquired using each of two or more matrixes different from one another; and removing, from each detection spectrum, a peak of a corresponding matrix to obtain a matrix-removed spectrum, and then acquiring a corrected mass spectrum of the analyte on the basis of a matrix-removed spectrum for each of different matrixes.
H01J 49/16 - Sources d'ionsCanons à ions utilisant une ionisation de surface, p. ex. émission thermo-ionique ou photo-électrique
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
A gas sample analysis apparatus and a gas sample analysis method, according to the present invention, can estimate a flow rate and a time enabling a gas sample to be concentrated to a gas sample concentration suitable for analysis, that is, a required concentration amount, thereby remarkably reducing total analysis time including gas sample concentration time, and can allow a suitable amount of a sample required for quantitative analysis to be concentrated and analyzed, thereby increasing analysis accuracy and preventing a problem in which overall analysis efficiency deteriorates.
The present invention relates to a double-helix oligonucleotide construct comprising a double-stranded miRNA and a composition for preventing or treating cancer comprising the same. More particularly, the present invention relates to a double-helix oligonucleotide construct comprising miR-544a characterized by a method that effectively inhibits the proliferation of cancer cells or induces a voluntary death of cancer cells, and an anticancer composition comprising the construct.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A biological sample processing apparatus, including: a pipette block with which a plurality of pipettes for sucking or discharging a biological sample in a multi-well plate in which wells are arranged in a matrix shape along row and column directions are detachably coupled; a pipette block forward and backward transfer unit configured to move the pipette block along a forward and backward direction along a process direction; a pipette block top and bottom transfer unit configured to move the pipette block along a vertical direction; a magnetic field applying unit disposed below the multi-well plate for applying a magnetic field to a well of the multi-well plate; and a heating unit disposed below the multi-well plate so as to be spaced apart from the magnetic field applying unit, for heating a well of the multi-well plate.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
The present invention relates to a device which is easy to use and in which real-time reaction product detection through nucleic acid extraction from a biospecimen, a PCR reaction, and scanning of excitation light of various wavelengths and fluorescence corresponding thereto can be automated, various tests can be carried out in a single operation, and in particular, accurate results can be obtained in a short amount of time.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
B01L 7/00 - Appareils de chauffage ou de refroidissementDispositifs d'isolation thermique
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
A biosample collection device capable of accurately examining a biosample is disclosed. The biosample collection device comprises a housing, a cap part and a biosample treatment solution storing part. The cap part is fastened to the housing so as to be detachable therefrom, and has a biosample collection part for collecting a biosample. The biosample treatment solution storing part stores a biosample treatment solution, and is damaged when the cap part is fastened to the housing after the biosample is collected by the biosample collection part, so as to mix the biosample treatment solution with the biosample.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Anti-diabetic functional lactic acid bacteria for use in food manufacture Microorganisms for medical purposes, namely, the treatment of obesity, Microorganisms for medical purposes, namely, the treatment of obesity, diabetes, atopy, visceral fat decrease; Probiotic microorganisms for medical purposes, namely, the treatment of obesity, diabetes, atopy, visceral fat decrease; Lactic acid bacterial preparations for medical use, namely, functional lactic acid bacteria for body fat breakdown and anti-obesity, functional lactic acid bacteria for improving immunity, functional lactic acid bacteria for improving skin diseases and atopic diseases and functional lactic acid bacteria for improving intestinal function and irritable colon symptoms; Medicines for the prevention and treatment of obesity, immune disorder, skin diseases, atopic diseases and intestinal disorders for veterinary purposes; Health food supplements based on milk for medical use containing probiotics in capsule, tablet and powder form; Dietary supplements containing probiotics for medical purposes in capsule, tablet, and powder form; Dietary supplements
93.
DISPLAY DEVICE FOR MATRIX-ASSISTED LASER DESORPTION IONIZATION MASS SPECTRUM
The present invention relates to a display device for a matrix-assisted laser desorption ionization mass spectrum. Specifically, the display device, according to the present invention, comprises: a storage unit which stores data including information on the mass-to-charge ratio (m/z) of matrix-derived ions for each matrix and an original mass spectrum which is a mass spectrum acquired by means of the matrix-assisted laser desorption ionization of an analyte; an input unit which receives, as input, information on a matrix material used when acquiring the original mass spectrum; a signal processing unit which receives the information on the matrix material inputted into the input unit, is linked with the storage unit, and according to the information on the matrix material inputted via the input unit, removes, from the original mass spectrum, a peak corresponding to the mass-to-charge ratio (m/z) of matrix-derived ions of the corresponding matrix material, thereby generating a noise-removed mass spectrum which is a mass spectrum having noise removed therefrom; and an output unit which receives the noise-removed mass spectrum from the signal processing unit and outputs same.
A sample plate for MALDI mass spectrometry, according to the present invention, enables separately positioning, by means of a plastic insulation plate, metal wiring and metal dots onto which an analyte sample is to be loaded, and electrically connecting same by means of a via or a metal portion, and thus the energy transferred into the plate when radiating a laser beam on the target (metal dots) may be reduced compared to a sample plate using a base metal, and thus laser energy may be concentrated on the target, and an effect may be achieved whereby heat loss is minimized.
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
biological enzymes for non-medical use; compositions for use in cDNA synthesis for research purposes; kits for use in cDNA synthesis for research purposes comprised of reagents, buffers, reverse transcriptase, oligomer; compositions for use in nucleic acid fluorescence staining for research purposes; kits for use in nucleic acid fluorescence staining for research purposes consisting of reagents, buffers, staining reagents; compositions for use in DNA sequence analysis for research purposes; kits for use in DNA sequence analysis for research purposes consisting of reagents, buffers, DNA polymerase; nucleic acid polymerase for research purposes; compositions for use in nucleic acid amplification for research purposes; kits for use in nucleic acid amplification for research purposes consisting of reagents, buffers, nucleic acid polymerase; chemical reagents for research purposes; compositions for use in polymerase chain reaction for research purposes; compositions for use in reverse transcription for research purposes. biological enzymes for medical use; kits for use in cDNA synthesis for medical purposes comprised of reagents, buffers, reverse transcriptase, oligomer; compositions for use in nucleic acid fluorescence staining for medical purposes; kits for use in nucleic acid fluorescence staining for medical purposes consisting of reagents, buffers, staining reagents; compositions for use in DNA sequence analysis for medical purposes; kits for use in DNA sequence analysis for medical purposes consisting of reagents, buffers, DNA polymerase; nucleic acid polymerase for medical purposes; compositions for use in nucleic acid amplification for medical purposes; kits for use in nucleic acid amplification for medical purposes consisting of reagents, buffers, nucleic acid polymerase; chemical reagents for medical purposes; compositions for use in reverse transcription for medical purposes.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
biological enzymes for non-medical use; compositions for use in cDNA synthesis for research purposes; kits for use in cDNA synthesis for research purposes comprised of reagents, buffers, reverse transcriptase, oligomer; compositions for use in nucleic acid fluorescence staining for research purposes; kits for use in nucleic acid fluorescence staining for research purposes consisting of reagents, buffers, staining reagents; compositions for use in DNA sequence analysis for research purposes; kits for use in DNA sequence analysis for research purposes consisting of reagents, buffers, DNA polymerase; nucleic acid polymerase for research purposes; compositions for use in nucleic acid amplification for research purposes; kits for use in nucleic acid amplification for research purposes consisting of reagents, buffers, nucleic acid polymerase; chemical reagents for research purposes; compositions for use in polymerase chain reaction for research purposes; compositions for use in reverse transcription for research purposes biological enzymes for medical use; kits for use in cDNA synthesis for medical purposes comprised of reagents, buffers, reverse transcriptase, oligomer; compositions for use in nucleic acid fluorescence staining for medical purposes; kits for use in nucleic acid fluorescence staining for medical purposes consisting of reagents, buffers, staining reagents; compositions for use in DNA sequence analysis for medical purposes; kits for use in DNA sequence analysis for medical purposes consisting of reagents, buffers, DNA polymerase; nucleic acid polymerase for medical purposes; compositions for use in nucleic acid amplification for medical purposes; kits for use in nucleic acid amplification for medical purposes consisting of reagents, buffers, nucleic acid polymerase; chemical reagents for medical purposes; compositions for use in nucleic acid amplification for medical purposes; compositions for use in reverse transcription for medical purposes
97.
Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.
A23L 33/135 - Bactéries ou leurs dérivés, p. ex. probiotiques
A23C 9/123 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes ne comportant que des micro-organismes de la famille des lactobactériacéesYoghourt
C07K 14/335 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Lactobacillus (G)
A61K 38/00 - Préparations médicinales contenant des peptides
98.
SAMPLE PLATE FOR MATRIX-ASSISTED LASER DESORPTION/IONISATION (MALDI) MASS SPECTROMETRY, AND MASS SPECTROMETRY METHOD USING SAME
The present invention relates to a sample plate for matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry, and a mass spectrometry method using the same. The sample plate according to the present invention comprises: a conductive substrate; and an organic matrix region which is formed on one surface of the conductive substrate, and in which two or more different organic matrices are arranged so as to be spaced apart from one another.
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p. ex. fermetures étanches au videDispositions pour le réglage externe des composants électronoptiques ou ionoptiques
99.
MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY METHOD
The present invention relates to a matrix-assisted laser desorption ionization mass spectrometry method and, specifically, a mass spectrometry method according to the present invention comprises the steps of: acquiring a mass spectrum of an analyte by performing matrix-assisted laser desorption ionization of the analyte, wherein a detection spectrum, which is the mass spectrum of the analyte, is acquired using each of two or more matrixes different from one another; and removing, from each detection spectrum, a peak of a corresponding matrix to obtain a matrix-removed spectrum, and then acquiring a corrected mass spectrum of the analyte on the basis of a matrix-removed spectrum for each of different matrixes.
G01N 27/62 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'ionisation des gaz, p. ex. des aérosolsRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant les décharges électriques, p. ex. l'émission cathodique
H01J 49/16 - Sources d'ionsCanons à ions utilisant une ionisation de surface, p. ex. émission thermo-ionique ou photo-électrique
The present invention relates to an epoxy paste composition including silver-coated copper nanowires having a core-shell structure, and a conductive film including the same.
C09D 7/00 - Caractéristiques de compositions de revêtement non prévues dans le groupe Procédés pour l’incorporation d’ingrédients dans des compositions de revêtement
C09D 163/00 - Compositions de revêtement à base de résines époxyCompositions de revêtement à base de dérivés des résines époxy